Phytohemagglutinin (PHA) renders human peripheral T lymphocytes competent to replicate their DNA and divide. The stimulation of peripheral T cells of the T4 phenotype by PHA, which appears to be a transcription-dependent event, leads to the production and release of lymphokines supporting proliferation and differentiation of human pluripotent stem cells (CFU-GEMMT). Supernatants of PHA-stimulated lymphocytes of the suppressor/cytotoxic phenotype (T8) failed to demonstrate reasonable activity to support the growth of CFU-GEMMT. Stimulation of T lymphocytes of the T4 but not of the T8 phenotype leads to an increased intracellular level of c-myc mRNA. This would be consistent with the c-myc gene product functioning as an intracellular mediator of the growth and lymphokine production response to PHA. Although the function of the c-myc gene product is not yet clear, it seems likely that it is involved in the control of cell proliferation. Such a contribution to control of cell proliferation by c-myc would probably be mediated by a family of genes inducing lymphokine production to stimulate proliferation of human pluripotent stem cells.

This content is only available via PDF.
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.